Cannabidiol modulation of hippocampal glutamate in early psychosis

被引:19
作者
O'Neill, Aisling [1 ,2 ]
Annibale, Luciano [1 ]
Blest-Hopley, Grace [1 ]
Wilson, Robin [1 ]
Giampietro, Vincent [3 ]
Bhattacharyya, Sagnik [1 ]
机构
[1] Kings Coll London, Dept Psychosis Studies, London, England
[2] Royal Coll Surgeons Ireland, Dept Psychiat, Dublin, Ireland
[3] Kings Coll London, Dept Neuroimaging, London, England
基金
英国医学研究理事会;
关键词
Cannabidiol; psychosis; glutamate; proton magnetic resonance spectroscopy; hippocampus; schizophrenia; PREFRONTAL CORTEX; MEMORY FUNCTION; HIGH-RISK; SCHIZOPHRENIA; DELTA-9-TETRAHYDROCANNABINOL; DYSFUNCTION; RECEPTORS; SYMPTOMS; DOPAMINE; BRAIN;
D O I
10.1177/02698811211001107
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Emerging evidence supports the antipsychotic effect of cannabidiol, a non-intoxicating component of cannabis, in people with psychosis. Preclinical findings suggest that this antipsychotic effect may be related to cannabidiol modulating glutamatergic signalling in the brain. Aim: The purpose of this study was to investigate the effects of cannabidiol on the neurochemical mechanisms underlying psychosis. Methods: We investigated the effects of a single oral dose of cannabidiol (600 mg) in patients with psychosis, using a double-blind, randomised, placebo-controlled, repeated-measures, within-subject cross-over design. After drug administration, 13 patients were scanned using proton magnetic resonance spectroscopy to measure left hippocampal glutamate levels. Symptom severity was rated using the Positive and Negative Syndrome Scale 60 min before drug administration (pre-scan), and 270 min after drug administration (post-scan). Effects of cannabidiol on hippocampal glutamate levels, symptom severity, and correlations between hippocampal glutamate and symptoms were investigated. Results: Compared to placebo, there was a significant increase in hippocampal glutamate (p=0.035), and a significantly greater decrease in symptom severity (p=0.032) in the psychosis patients under cannabidiol treatment. There was also a significant negative relationship between post-treatment total Positive and Negative Syndrome Scale score and hippocampal glutamate (p=0.047), when baseline Positive and Negative Syndrome Scale score, treatment (cannabidiol vs placebo), and interaction between treatment and glutamate levels were controlled for. Conclusions: These findings may suggest a link between the increase in glutamate levels and concomitant decrease in symptom severity under cannabidiol treatment observed in psychosis patients. Furthermore, the findings provide novel insight into the potential neurochemical mechanisms underlying the antipsychotic effects of cannabidiol.
引用
收藏
页码:814 / 822
页数:9
相关论文
共 84 条
  • [1] Resting Hyperperfusion of the Hippocampus, Midbrain, and Basal Ganglia in People at High Risk for Psychosis
    Allen, Paul
    Chaddock, Christopher A.
    Egerton, Alice
    Howes, Oliver D.
    Bonoldi, Ilaria
    Zelaya, Fernando
    Bhattacharyya, Sagnik
    Murray, Robin
    McGuire, Philip
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2016, 173 (04) : 392 - 399
  • [2] Abnormalities in neuroendocrine stress response in psychosis: the role of endocannabinoids
    Appiah-Kusi, E.
    Leyden, E.
    Parmar, S.
    Mondelli, V.
    McGuire, P.
    Bhattacharyya, S.
    [J]. PSYCHOLOGICAL MEDICINE, 2016, 46 (01) : 27 - 45
  • [3] Bartha R, 1997, ARCH GEN PSYCHIAT, V54, P959
  • [4] Targeting glutamate to treat schizophrenia: lessons from recent clinical studies
    Beck, Katherine
    Javitt, Daniel C.
    Howes, Oliver D.
    [J]. PSYCHOPHARMACOLOGY, 2016, 233 (13) : 2425 - 2428
  • [5] Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders
    Beneyto, Monica
    Kristiansen, Lars V.
    Oni-Orisan, Akinwunmi
    McCullumsmith, Robert E.
    Meador-Woodruff, James H.
    [J]. NEUROPSYCHOPHARMACOLOGY, 2007, 32 (09) : 1888 - 1902
  • [6] Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of δ-9-tetrahydrocannabinol on midbrain and striatal function
    Bhattacharyya, S.
    Atakan, Z.
    Martin-Santos, R.
    Crippa, J. A.
    Kambeitz, J.
    Prata, D.
    Williams, S.
    Brammer, M.
    Collier, D. A.
    McGuire, P. K.
    [J]. MOLECULAR PSYCHIATRY, 2012, 17 (12) : 1152 - 1155
  • [7] Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis A Randomized Clinical Trial
    Bhattacharyya, Sagnik
    Wilson, Robin
    Appiah-Kusi, Elizabeth
    O'Neill, Aisling
    Brammer, Michael
    Perez, Jesus
    Murray, Robin
    Allen, Paul
    Bossong, Matthijs G.
    McGuire, Philip
    [J]. JAMA PSYCHIATRY, 2018, 75 (11) : 1107 - 1117
  • [8] Cannabinoid Modulation of Functional Connectivity within Regions Processing Attentional Salience
    Bhattacharyya, Sagnik
    Falkenberg, Irina
    Martin-Santos, Rocio
    Atakan, Zerrin
    Crippa, Jose A.
    Giampietro, Vincent
    Brammer, Mick
    McGuire, Philip
    [J]. NEUROPSYCHOPHARMACOLOGY, 2015, 40 (06) : 1343 - 1352
  • [9] Induction of Psychosis by Δ9-Tetrahydrocannabinol Reflects Modulation of Prefrontal and Striatal Function During Attentional Salience Processing
    Bhattacharyya, Sagnik
    Crippa, Jose Alexandre
    Allen, Paul
    Martin-Santos, Rocio
    Borgwardt, Stefan
    Fusar-Poli, Paolo
    Rubia, Katya
    Kambeitz, Joseph
    O'Carroll, Colin
    Seal, Marc L.
    Giampietro, Vincent
    Brammer, Michael
    Zuardi, Antonio Waldo
    Atakan, Zerrin
    McGuire, Philip K.
    [J]. ARCHIVES OF GENERAL PSYCHIATRY, 2012, 69 (01) : 27 - 36
  • [10] Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology
    Bhattacharyya, Sagnik
    Morrison, Paul D.
    Fusar-Poli, Paolo
    Martin-Santos, Rocio
    Borgwardt, Stefan
    Winton-Brown, Toby
    Nosarti, Chiara
    O'Carroll, Colin M.
    Seal, Marc
    Allen, Paul
    Mehta, Mitul A.
    Stone, James M.
    Tunstall, Nigel
    Giampietro, Vincent
    Kapur, Shitij
    Murray, Robin M.
    Zuardi, Antonio W.
    Crippa, Jose A.
    Atakan, Zerrin
    McGuire, Philip K.
    [J]. NEUROPSYCHOPHARMACOLOGY, 2010, 35 (03) : 764 - 774